Blood pressure–lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria)
2017
To examine the antihypertensive efficacy and safety of
indapamidesustained-release (SR)/
amlodipinecompared with
enalapril/
amlodipinein patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a
post hoc analysisof the NESTOR trial (Natrilix SR vs
Enalaprilin Hypertensive Type 2 Diabetics With
Microalbuminuria) was conducted. NESTOR randomized 570 patients (n=197, aged ≥65 years) with hypertension (systolic BP 140–180/diastolic BP <110 mm Hg) to
indapamideSR 1.5 mg or
enalapril10 mg. If target BP (<140/85 mm Hg) was not achieved at 6 weeks,
amlodipine5 mg was added with uptitration to 10 mg if required. A total of 107 patients aged 65 years and older received dual therapy (53
indapamideSR/
amlodipineand 54
enalapril/
amlodipine).
Amlodipineuptitration occurred in 22 and 24 patients, respectively. At 52 weeks, mean systolic BP (±SE) reduction was significantly greater with
indapamideSR/
amlodipinevs
enalapril/
amlodipine6.2±2.7 mm Hg (P=.02).
IndapamideSR/
amlodipinewas also associated with a greater BP response rate (88% vs 75%, respectively). Both regimens were well tolerated.
IndapamideSR/
amlodipinemay be more effective than
enalapril/
amlodipinefor lowering systolic BP in patients with hypertension aged 65 years and older.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
40
References
2
Citations
NaN
KQI